Connect with us

Nasdaq: MGRX Profile

Mangoceuticals, Inc. logo

OUR NEW PROFILE IS:   (NASDAQ: MGRX)

52% of men experience some form of erectile dysfunction throughout their life and that total increases anywhere from 5-15% between ages 40 and 70

Mangoceuticals Engages Premier Global Software Development Firm, RedLime Solutions to Expand Technology Platform to Accommodate Increased Customer Flow

Mangoceuticals, Inc.’s Debut Commercial Surpasses 8 Million Views on YouTube

Mangoceuticals Engaged by Social Media Sensation Adam22 as Exclusive New Sponsor of Hit Podcasts with Skyrocketing Male Engagement

*****BREAKING NEWS RELEASED THIS MORNING*****

Mangoceuticals Partners with Greater NY Chamber of Commerce for Mass Marketing & Sales of Flagship Mango Product

MangoRx enters the NY market with the full force of the GNYCC with over 30,000+ business & civic leaders who represent the backbone of the Greater New York area

Dallas, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce its new partnership with the Greater NY Chamber of Commerce (“GNYCC”) to bring its flagship product, Mango, to New York as part of a major nationwide push to drive accelerating sales growth and new avenues of marketing for its core product portfolio.

New York consistently features in the top five U.S. states for most erectile dysfunction medication sales. Mangoceuticals is targeting accelerating nationwide sales and seeks to enter the NY marketplace to augment the splash it is seeing in its new Make America Hard Again campaign.

“This is an exciting time for Mangoceuticals as we partner with one of the largest Chambers of Commerce in the U.S. to drive sales growth and brand awareness and pursue new channels of market penetration in one of the biggest regional markets in the country,” commented Jacob Cohen, CEO and Co-Founder of Mangoceuticals. “We have already established a strong presence in NY on a brand basis, so it’s only fitting that our flagship Men’s ‘erectile function’ medication, Mango, will be our first core product to benefit from a huge direct sales push in this pivotal market.”

The Greater New York Chamber of Commerce represents 30,000 business and civic leaders, each of whom will receive complimentary access to Mango as the GNYCC launches their new Men’s Health & Wellness committee. The GNYCC’s members and partners are comprised of entrepreneurs, small, medium size, major and international corporations, public officials, local, city, state and federal agencies, foreign dignitaries, and consulates.

In 2022, North America dominated the global erectile dysfunction drugs market with the highest revenue share of 51.7% and the U.S. sexual wellness market size was valued at USD 11.0 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.91% from 2023 to 2030, according to recent analysis from Grand View Research.

“The Greater New York Chamber is proud to have MangoRx come to New York and be an elite member as they seek to help so many Americans across the Country with both erectile function and the many health & wellness products they intend to release,” commented Mark Jaffe, the President and CEO of the Greater New York Chamber. “The NY launch of their flagship medication to all of our members is just the tip of the iceberg for MangoRx and the GNYCC.”

Management notes that MangoRx continues to broaden and deepen its marketing and sales footprint, with its latest partnership with GNYCC as one of many key steps to drive its nascent nationwide push. This follows recent steps including its appointment of the award winning Lucky Break PR firm, its sponsorship relationships with leading social media and podcast brands focused on the men’s demographic, such as Barstool Sports, Only Stans, Pillow Talk and No Jumper, as well as the nationwide launch of its “Make America Hard Again” (www.MakeAmericaHardAgain.com) campaign. These steps pave the way for the Company’s upcoming launch of its new sildenafil-based Mango ED product, which contains the active ingredient found in Viagra™, along with many other new and disruptive products now in the pipeline.

About the Greater New York Chamber of Commerce

The Greater New York Chamber of Commerce represents 30,000 business and civic leaders comprising of entrepreneurs, small, medium size, major and international corporations, public officials, local, city, state and federal agencies, foreign dignitaries, and consulates. It provides in-person and online weekly networking receptions, breakfasts, luncheons, seminars, and business expos.

The mission of the Chamber is to improve the business climate and quality of life in the New YorkMetropolitan Area for businesses, workers, residents, and visitors. It provides valuable services to individuals, start-ups, entrepreneurs, small businesses, and civic leaders who represent the backbone of the Greater New York business community.

The Greater New York Chamber of Commerce is an approved New York State Not for Profit entity. It operates under Rule 501 C 6, as an exempt organization under the U.S. Internal Revenue Code. It also maintains a charitable fund to help assist local chambers, trade organizations and civic groups under IRS Rule 501 C 3 and a political action committee.

________________________________________________

Hello Everyone,

Our last profile certainly did not disappoint. It saw an average trade of 2.21 on Monday and it tapped 3.05 during Tuesdays session before pulling back.

We have a recent profile back on our radar that we want you to research again for Wednesdays session.

Pull up MGRX immediately.

Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name “Mango” (think “Man Go”).

Created using a special formulation featuring the same active ingredient as in Cialis (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.

Mango is a prescription medication that must be approved by a physician. After an individual has completed an online telehealth visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Tadalafil, one of the main ingredients in Mango, typically has effects that last up to 36 hours.

MangoRx recently concluded its successful IPO on the Nasdaq Capital Market, generating $5,000,000 in gross proceeds. These funds will be utilized to finance marketing and operational expenses related to the planned launch of their flagship Mango product. Additionally, the proceeds will support talent acquisition, software development, and general corporate purposes.

Mangoceuticals is making waves in the men’s health market with its innovative approach and commitment to redefining the standards for ED treatment. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers.

The men’s health sector is ripe with potential, offering attractive opportunities as companies meet the growing demand for male-centric wellness solutions. Recent market research projects a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors. A confluence of factors, including a rise in men’s health awareness, a paradigm shift in societal norms that emphasize self-care, and ground-breaking developments in medical technology and research, are just a few of the factors driving the growth in this sector.

The men’s health market encompasses a diverse range of products and services, including pharmaceuticals, dietary supplements, fitness equipment, personal care products, telehealth services, and tailored wellness programs. These offerings cater to various aspects of men’s health, including physical fitness, mental wellness, and nutritional support.

Beyond product offerings, Mangoceuticals understands the importance of education and information in men’s health. MangoRx is dedicated to providing comprehensive knowledge and resources, empowering men to make informed decisions about their well-being. By sharing information confidently and breaking down barriers, Mangoceuticals is destigmatizing the conversation around men’s health.

MangoRx offers a convenient telemedicine platform, allowing men to access their products without leaving their homes. By eliminating the need for in-person doctor visits, MangoRx provides a discreet and accessible solution for men’s health needs. With a streamlined process, users can create an account, complete a telemedicine session, and have their prescribed products delivered to their doorstep.

The MangoRx approach differs from other ED treatments in its commitment to education and refreshing approach to the topic. While the subject matter is serious, MangoRx embraces a fun and confident attitude. By injecting humor into their brand, they aim to empower men on their journey to better health, ensuring that the pursuit of ‘intimate well-being’ is an enjoyable experience.

Mango (Man-Go)

Mango, Mangoceuticals’ flagship product, is a groundbreaking solution designed to address men’s unique concerns. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers. Crafted with FDA-approved ingredients, Mango combines a selection of compounds to target the challenges men face in intimate situations.

Mango stands out with its rapid-dissolving mango-flavored tablets, which deliver quicker results by efficiently entering the bloodstream. These sublingual Rapid Dissolving Tablets (RDTs) contain the same active ingredient as Cialis (tadalafil), as well as the MGRX unique blend. By incorporating this combination, Mango offers a tasty, efficient, and powerful solution for men seeking faster relief from the symptoms of ED.

Earlier this month, MGRX announced via Twitter that Mango is now available in Nevada. This expansion marks a significant milestone for Mangoceuticals as they continue to broaden their market reach and offer their cutting-edge men’s health and wellness products to new potential customers.

Mango is now available in 44 states, including Nevada and the District of Columbia.

Mangoceuticals Engaged by Social Media Sensation Adam22 as Exclusive New Sponsor of Hit Podcasts with Skyrocketing Male Engagement

Dallas, Texas, July 18, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce that it has been engaged as an exclusive new sponsor by Adam22 and will be featured on a series of No Jumper and Plug Talk episodes beginning in August 2023 ( https://www.youtube.com/@NoJumper).

“Adam22 has his finger on the pulse of a demographic that represents an excellent fit for MangoRx, providing a new road to achieving our revenue growth targets by reaching large audiences and promoting our products nationwide,” stated MGRX Co-Founder and CEO, Jacob Cohen. “Our focus right now is on driving powerful sales growth. This partnership holds the potential to create an enormous bump in brand awareness, sales, and market share in the growing men’s health and wellness marketplace, and we look forward to working with Adam and his team beginning next month.”

Both the No Jumper and Plug Talk podcasts have grown to amass large engaged audiences. The No Jumper social media universe has amassed nearly 12 million followers across YouTube, Instagram, Tik Tok, Twitter, and Snapchat. Nearly 90% of those followers are male, and 93% are between 18-44 years of age, suggesting a very strong correlation between the MangoRx target market and the large and growing No Jumperaudience.

Moreover, each No Jumper podcast episode averages 100-150k views/downloads, with the No Jumper channel receiving approximately 20 million monthly views. Plug Talk is new, but growing extremely fast, with 30 thousand new subscribers per month and over 50 thousand views per episode.

“We welcome MangoRx on board with open arms,” stated Josh Manheim, Chief Operating Officer of No Jumper. “We look forward to working with Jacob and his team, and we really believe this is a situation where everyone’s interests are very well aligned toward a mutually beneficial outcome. MangoRx is a disruptive new face in its marketplace, and they are once again proving that identity with this partnership.”

The Company plans on sponsoring at least 8 episodes of No Jumper and 2 episodes of Plug Talk during August and September, with more brand involvement potentially in the works. Promotional spots will feature the show’s hosts speaking organically about MangoRx and its products for at least a full minute.

Cohen continued, “Past No Jumper episodes have reached into the tens of millions of views, reaching a huge audience that is extremely well-aligned with our target market demographic. The show’s most recent episode hit 10 thousand views within two hours of being posted. This is a cultural phenomenon with enormous traction. Our promotional spots should be highly impactful, with at least a full minute of organic airtime devoted to MangoRx and our products and vision. We couldn’t be more excited about the opportunity this represents.”

Mangoceuticals, Inc. Announces Upcoming Launch of its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Dallas, Texas, June 21, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling multiple men’s health and wellness products through a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug, “Mango,”, is pleased to announce the upcoming release of its second Mango ED product leveraging the Company’s existing custom compound alongside Sildenafil, which is the active ingredient found in Viagra.

The launch of the Company’s Sildenafil based Mango ED product is scheduled to be available for purchase online this summer. Like the Company’s currently marketed and sold Tadalafil based Mango ED product, which leverages the same active ingredient found in Cialis, the new Sildenafil-based Mango will still be compounded with Oxytocin and L-Arginine in a tasty Mango-flavored rapid dissolve tablet (RDT) and individually packaged in a master pack of six tablets per package.

“Our intent with the launch of this new product is to establish Mango as a legitimate competitor armed with the biotechnology behind Tadalafil and Sildenafil, both of which are the two runaway winners in the ED space over the past two decades,” noted Jacob Cohen, CEO and Co-Founder of MangoRx. “The ED market has already proven to be big enough to accommodate multiple competing products. Some people like Pepsi and others prefer Coca-Cola. Tadalafil and Sildenafil are both effective biotech solutions and we believed it was important to make both options available in order to capture additional market share and not exclude potential customers based on personal preferences.”

Management also notes that Tadalafil and Sildenafil each have their own unique properties, which can lead to different manifest effects among users. For example, Tadalafil has been proven to last longer than Sildenafil due to a half-life more than four times as long. At the same time, Sildenafil may reach full efficacy faster than Tadalafil. But the most important point is that each has cultivated its own sizeable following and both compounds can be effectively integrated into MangoRx’s specialty compounded formula.

Management is also very encouraged by the buzz generated through its recently expanded marketing activities.

Cohen concluded, “We are extremely pleased with our recent efforts and sponsorships with Barstool Sports and GaS Digital Networks and we only intend to get more aggressive with our marketing efforts in the upcoming months as we market our new Sildenafil based Mango ED product. There’s a real buzz and it’s growing. That sense should be amplified further by additional new products that we intend to launch in the upcoming months. Overall, it’s an exciting time for the Company, and we have a lot more excitement to come as we continue to focus on taking market share through the further development of innovative product formulas, superior branding, marketing initiatives and product design.”

Mangoceuticals Engages Premier Global Software Development Firm, RedLime Solutions to Expand Technology Platform to Accommodate Increased Customer Flow

Dallas, Texas, Aug. 01, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce that it has engaged RedLime Solutions (“RedLime”), a global software development and IT Consulting company as its software support and development provider. Redlime has worked with major companies such as Pepsi, Nokia, Pizza Hut, and AT&T having developed various custom software solutions for them and their partners.

“Bringing the RedLime team into the equation is a significant step toward engaging more customers, elevating the MangoRx customer experience, reducing the friction around expanding our product offerings, and laying a foundation for accelerating growth through new strategies, features, and verticals,” remarked Jacob Cohen. Mangoceuticals, Inc.’s Co-Founder and CEO. “This will add eight top-tier dedicated software developers to our already talented team, unleashing a new dimension to our growth outlook as we shift into a new gear focused on commercialization of new, innovative men’s health and wellness products and financial performance.”

Management notes that the partnership with RedLime is anticipated to:

  • Add additional features to the current customer journey and experience.
  • Expand customer support functionality including automation and other support features.
  • Streamline the addition of new products to the platform.
  • Expand development and support in anticipation of our affiliate marketing platform.
  • Drive new development projects that both enhance the current experience and for additional features and verticals to support future revenue generating opportunities.

Tom Joardar, CEO of RedLime, commented, “We are excited about the opportunity to work with MangoRx to help facilitate the realization of its disruptive vision. The Company is anticipating significant demand growth following recent strides in marketing and visibility. It will be our job to help them handle this increased demand by enhancing and augmenting the MangoRx telemedicine platform on the back end to accommodate substantially increased traffic and customer flow.”

MangoRx has recently commenced expanding its marketing footprint, in part with its recent sponsorship relationships with leading social media and podcast brands focused on the men’s demographic, such as Barstool Sports, Only Stans, Pillow Talk and No Jumper, as well as the nationwide launch of its “Make America Hard Again” ( www.MakeAmericaHardAgain.com ) campaign.

This expanded visibility comes in step with the upcoming launch of the Company’s new sildenafil based Mango ED product, which contains the active ingredient found in Viagra . This accompanies its original Mango Tadalafil flagship product, which contains the active ingredient found in Cialis . Both products contain the Company’s proprietary and unique blend of ingredients found in FDA approved products, including Oxytocin and L-Arginine, and both are delivered via a rapidly dissolving mango-flavored tablet that activates and dissolves orally for faster results.

Cohen continued, “This partnership accomplishes two of our main objectives right now: to establish a new technology foundation capable of keeping up with significant demand growth, and to set the stage for frictionless expansion into new verticals focused on the growing men’s health and wellness marketplace. This is a big piece of the puzzle coming into place and we look forward to working with Tom and his very talented Redlime team.”

 

Mangoceuticals, Inc.’s Debut Commercial Surpasses 8 Million Views on YouTube

NEWS 

PUBLISHED
JUL 18, 2023

Mangoceuticals Engaged by Social Media Sensation Adam22 as Exclusive New Sponsor of Hit Podcasts with Skyrocketing Male Engagement

MANAGEMENT

 

Photo of Jacob Cohen

Jacob Cohen

Co-Founder and Chief Executive Officer

Jacob Cohen is a serial entrepreneur, corporate finance and executive management professional with over 20 years of investment banking and capital markets experience having started and growing multiple companies in various industry sectors including marketing, advertising, healthcare, IT and financial services. Prior to founding the Company, Mr. Cohen was the co-founder and managing partner of several boutique investment bank and strategic advisory firms where he advised both early and later stage companies in raising capital in the form of debt and/or equity and in both private and public markets.

Prior to his experiences in investment banking, Mr. Cohen served as the Chief Financial Officer of The Renewed Group, Inc., a manufacturer, wholesaler and retailer of eco-friendly and sustainable apparel primarily made from recycled textiles and under the brand name REUSE JEANS from 2010 through the end of 2013. Further, Mr. Cohen served from 2008 through 2010 as Executive Vice President and Controller of Metiscan, Inc., a publicly traded company, and as the President and Chief Executive Officer of one of its subsidiaries, Shoreline Employment Services, Inc. During his tenure at Metiscan, Mr. Cohen was instrumental in restructuring, reorganizing and operating the company and its five subsidiaries, and successfully raised over $8 million in equity financing for growth capital. Mr. Cohen also spearheaded the company’s financial audit process and managed its various filings with the SEC.

From 2007 through 2008, Mr. Cohen served as the Chief Operating Officer of Artfest International, which he assisted in taking public at the end of 2007. Throughout his career, Mr. Cohen was involved in starting many new ventures, including The AdvertEyes Network, a digital signage advertising company where he served as founder and CEO. Other positions include investment advisor and institutional equity research analyst for Solomon Advisors and Huberman Financial, securities broker-dealers, from 2003 through 2005, and investment banker for Allegiance Capital, a middle market investment bank specializing on mergers and acquisitions, from 2005-2007. Mr. Cohen holds a Bachelor of Arts in International Economics and Finance from Brandeis University in Waltham, Massachusetts.

Mr. Cohen has served as Chief Executive Officer of the Company since October 2021, as a director from October 2021 to present, and as Chairman from September 2022 to present. Mr. Cohen also currently serves as Chief Executive Officer and as a director of American International Holdings Corp (“American International”), a publicly traded company which is the majority owner and parent to Epiq Scripts, LLC, and which is the former sole owner of the Company, having fully divested its ownership in June 2022, and as Chief Executive Officer of Ronin Equity Partners, Inc., a private investment company, which role he has held since August 2016. Mr. Cohen also serves the Chief Executive Officer of Cohen Enterprises, Inc., a private investment company, which position he has held since November 2013.

Jonathan Arango is a Business Development Executive with more than 10 years of hands-on experience in pharmacy operations and management, business development, team management, and strategic relationship development. He has a history of driving significant revenue growth for companies in multiple sectors. Mr. Arango participates in numerous ambitious ventures, spanning multiple industries such as e-commerce, medical & health, restaurants, and cryptocurrency.

Photo of Jonathan Arango

Jonathan Arango

Co-Founder and President

Mr. Arango has served as the Co-Founder, President and Director of the Company since October 2021. Prior to his appointment to the Company, Mr. Arango served as Chief Operating Officer of Murphy Rx LLC, a retail and specialty pharmacy based out of Murphy, Texas, which he previously owned, from June 2020 to March 2022. Prior to owning a pharmacy, Mr. Arango founded and served as CEO of Golden Heights Medical Consulting, a healthcare marketing agency that specialized in customer acquisition and medical ancillary services from February 2017 to January 2019. He also served as an independent contractor providing marketing and sales services from April 2015 to February 2017.

Before entering the healthcare industry, Mr. Arango ran an independent marketing and sales agency from 2013 to 2018 (A&J Marketing). A&J Marketing was contracted by multiple companies spanning different industries to generate and substantially scale revenue in multiple sectors. Industries included were Home Improvement, Oil & Gas, Health & Wellness, Professional Development, and E-commerce.

Photo of Amanda Hammer

Amanda Hammer

Chief Operating Officer

Amanda Hammer has been a member of the MangoRx team since late 2022 and has been instrumental in launching and optimizing MangoRx’s eCommerce platform. She is a proven leader with a track record of success having recently completed a 4-year tenure at D Magazine Partners, a Dallas based multimedia company, where she held roles leading Audience Development, Brand, and Digital Operations, quickly rising to become the company’s first named Chief Operations Officer. Prior to that, Amanda worked in private equity consulting and assisting newly acquired business verticals with optimizing sales and marketing processes, improving subscription retention, and training new talent to enhance productivity and maximize revenue streams.

Amanda obtained dual Bachelor of Arts degrees—in Graphic Design and Communication Studies—from the University of Iowa. She has also obtained a Negotiation and Leadership Certificate from Harvard Law School and is a recent graduate of the Texas Women’s Foundation Leadership Institute.

Photo of Eugene M. Johnston

Eugene M. Johnston

Chief Financial Officer

Mr. Johnston has served as Chief Financial Officer of the Company since October 2022. Since February 2015, Mr. Johnston has served as Audit Manager for Greentree Financial Group, Inc., an accounting and auditing firm. From August 1999 to September 2014, Mr. Johnston served as Chief Executive Officer of Peoplesway.com, Inc., a skincare and nutritional products company, and from August 1999 to present, Mr. Johnston has served as a member of the Board of Directors of Peoplesway.com, Inc. From January 1999 to July 1999, Mr. Johnston served as Chief Executive Officer of RMC Group, Inc., a skincare and nutritional products company. Prior to that, from April 1987 to January 1989, Mr. Johnston served as Vice President of Sales Administration at WeCare Distributors, Inc., a skincare and nutritional products company.

Mr. Johnston received a Bachelor’s in Science in Business Administration from the University of North Carolina Charlotte.

Sincerely,

MICROCAPDAILY

© All rights reserved.